Daniel Bensen - 26 Jun 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Operating Officer
Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Issuer symbol
TYRA
Transactions as of
26 Jun 2023
Net transactions value
-$760,098
Form type
4
Filing time
28 Jun 2023, 20:31:53 UTC
Previous filing
15 Jun 2023
Next filing
03 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Options Exercise $10,512 +17,232 +3.3% $0.6100* 545,213 26 Jun 2023 Direct
transaction TYRA Common Stock Sale $179,132 -10,862 -2% $16.49 534,351 26 Jun 2023 Direct F1, F2
transaction TYRA Common Stock Sale $109,793 -6,370 -1.2% $17.24 527,981 26 Jun 2023 Direct F1, F3
transaction TYRA Common Stock Options Exercise $9,777 +16,028 +3% $0.6100* 544,009 27 Jun 2023 Direct
transaction TYRA Common Stock Sale $132,050 -7,893 -1.5% $16.73 536,116 27 Jun 2023 Direct F1, F4
transaction TYRA Common Stock Sale $139,025 -8,135 -1.5% $17.09 527,981 27 Jun 2023 Direct F1, F5
transaction TYRA Common Stock Options Exercise $8,250 +13,524 +2.6% $0.6100* 541,505 28 Jun 2023 Direct
transaction TYRA Common Stock Sale $228,637 -13,524 -2.5% $16.91 527,981 28 Jun 2023 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -17,232 -7.5% $0.000000 211,830 26 Jun 2023 Common Stock 17,232 $0.6100 Direct F7
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -16,028 -7.6% $0.000000 195,802 27 Jun 2023 Common Stock 16,028 $0.6100 Direct F7
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -13,524 -6.9% $0.000000 182,278 28 Jun 2023 Common Stock 13,524 $0.6100 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.
F2 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.01 to $17.005. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.02 to $17.69. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.01 to $17.01. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.02 to $17.20. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.50 to $17.09. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F7 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.